Scholar Rock Holding Corp (SRRK)
Healthcare
Biotechnology
47.30 $
-3.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Scholar Rock Holding Corp (SRRK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.6% of the shares are freely tradable; institutional investors hold 116.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
116.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
76.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
17.5%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
120Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.39 | 17,243,152 | +12.1 | 03/31/2026 |
| Siren, L.L.C. | 9.03 | 10,825,013 | +0.0 | 03/31/2026 |
| Redmile Group, LLC | 7.57 | 9,066,621 | +73.7 | 03/31/2026 |
| BlackRock Inc | 6.23 | 7,469,293 | +3.5 | 03/31/2026 |
| Samsara BioCapital, LLC | 5.76 | 6,897,652 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 5.61 | 6,717,655 | +16.6 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 5.18 | 6,206,618 | -3.1 | 03/31/2026 |
| Vanguard Group Inc | 4.34 | 5,195,465 | +5.7 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 4.94 | 5,922,929 | +2.4 | 04/30/2026 |
| Fidelity Growth Company Fund | 3.67 | 4,399,620 | +6.1 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.